Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ebos Group's annualized net income for the quarter that ended in Dec. 2023 was NZ$293 Mil. Ebos Group's average shareholder tangible equity for the quarter that ended in Dec. 2023 was NZ$-139 Mil. Therefore, Ebos Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was Negative Tangible Equity%.
The historical rank and industry rank for Ebos Group's Return-on-Tangible-Equity or its related term are showing as below:
NZSE:EBO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 80.83 Med: 107.86 Max: 557.92
Current: Negative Tangible Equity
During the past 13 years, Ebos Group's highest Return-on-Tangible-Equity was 557.92%. The lowest was 80.83%. And the median was 107.86%.
NZSE:EBO's Return-on-Tangible-Equity is ranked better than 98.94% of 94
companies
in the Medical Distribution industry
Industry Median: 8.115
vs NZSE:EBO: Negative Tangible Equity
Ebos Group Return-on-Tangible-Equity Historical Data
The historical data trend for Ebos Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ebos Group's Return-on-Tangible-Equity
For the Medical Distribution subindustry, Ebos Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group's Return-on-Tangible-Equity Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ebos Group's Return-on-Tangible-Equity falls into.
Ebos Group Return-on-Tangible-Equity Calculation
Ebos Group's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Ebos Group (NZSE:EBO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ebos Group Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Ebos Group's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low single digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NZSE:EBO has been successfully added to your 